The short answer
Chromium may add to insulin’s glucose-lowering effect, so supplement use warrants an individual monitoring plan. An insulin-aspart-specific risk or chromium requirement has not been established.
What this answer covers
Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
- Supplement or preparation
- Chromium
- Medication ingredient
- insulin aspart, human
Why the precaution applies
NIH guidance cautions that chromium may increase glucose-lowering effects when combined with insulin. Insulin aspart’s labels likewise call for review when other glucose-active treatments change. This is a conditional precaution, not a measured interaction rate.
The direct drug trial used glipizide
A chromium-picolinate study improved insulin sensitivity and glucose control in people taking glipizide GITS. Glipizide stimulates insulin secretion and is not injected insulin aspart. That study cannot quantify the risk for this pair.
No extra chromium need follows
The trial does not show that insulin aspart depletes chromium or that every insulin user should supplement. Chromium form, elemental dose and overlapping products need review, particularly with high-dose preparations.
Monitoring is more useful than assumed spacing
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. No hour-based gap has been shown to remove chromium’s possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
Federal insulin/chromium precaution supports monitoring, while the inspected drug trial is glipizide, not insulin aspart; no exact incidence or nutritional requirement.
- Exact scope
- Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium. with Insulin aspart human RxCUI51428 IN; NovoLog/Fiasp formulation and subcutaneous/pump/supervised intravenous routes distinguished.
- Medication form and route
- injected insulin aspart; oral supplement
What remains uncertain
- No source-specific uncertainty removed; no invented event rate or universal insulin adjustment.
Factors that may matter: Exact insulin product; Meal pattern; Dose; Other diabetes treatment; Kidney and liver function; Supplement preparation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact insulin aspart; source medication and supplement formulation are preserved.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement. This does not establish an exact insulin-aspart interaction.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Indirect for exact insulin aspart; source medication and supplement formulation are preserved.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial. This does not establish an exact insulin-aspart interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact insulin-aspart article with product, route, botanical and clinical endpoint boundaries. | |
| Research summary published |
Article revision: 8ba4c2a858bb1d99
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.